Loading…
Loading grant details…
| Funder | Swedish Research Council |
|---|---|
| Recipient Organization | Karolinska Institutet |
| Country | Sweden |
| Start Date | Jan 01, 2024 |
| End Date | Dec 31, 2026 |
| Duration | 1,095 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | Swedish Research Council |
| Grant ID | 2023-00537_VR |
ARID1B is the most frequently mutated single gene in neurodevelopmental disorders (NDDs) that are not inherited, with an approximated prevalence of one in 9,500 individuals.
ARID1B-related disorder (ARID1B-RD) manifests in early childhood as moderate to severe developmental delay, and children and adults with the disorder have intellectual disability and are often diagnosed with autism alongside many other clinical signs.
Despite ARID1B-RD’s high prevalence and extensive debilitating effects, the current understanding of how the disorder develops over time is strikingly limited. The proposed project will address this gap by employing a prospective longitudinal multi-method design. Specifically, we will monitor the development of 135 children and adolescents aged 2-18 with ARID1B-RD for 30 months.
Monitoring will involve a) administration of standardized NDD assessments by clinicians complemented by caregivers’ reports; b) evaluation of biological aspects of ARID1B-RD, and c) collection daily life data via caregivers’ reports, and auditory and activity data using microphones and smartwatches.
The project team brings a diverse complementary skills and collaborates with leading patient advocacy organizations. The project will generate a comprehensive picture of the progression of ARID1B-RD.
The generated data will allow identifying and validating measurable targets for interventions, thus facilitating the development of effective treatments for thousands of children worldwide.
Karolinska Institutet
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant